Genetic variants in anti-Müllerian hormone-related genes and breast cancer risk: results from the AMBER consortium

Hazel B. Nichols, Mariaelisa Graff, Jeannette T. Bensen, Kathryn L. Lunetta, Katie M. O’Brien, Melissa A. Troester, Lindsay A. Williams, Kristin Young, Chi Chen Hong, Song Yao, Christopher A. Haiman, Edward A. Ruiz-Narváez, Christine B. Ambrosone, Julie R. Palmer, Andrew F. Olshan

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Circulating anti-Müllerian hormone (AMH) levels are positively associated with time to menopause and breast cancer risk. We examined breast cancer associations with single nucleotide polymorphisms (SNPs) in the AMH gene or its receptor genes, ACVR1 and AMHR2, among African American women. Methods: In the AMBER consortium, we tested 65 candidate SNPs, and 1130 total variants, in or near AMH, ACVR1, and AMHR2 and breast cancer risk. Overall, 3649 cases and 4230 controls contributed to analyses. Odds ratios (OR) and 95% confidence intervals (CI) for breast cancer were calculated using multivariable logistic regression. Results: After correction for multiple comparisons (false-discovery rate of 5%), there were no statistically significant associations with breast cancer risk. Without correction for multiple testing, four candidate SNPs in ACVR1 and one near AMH were associated with breast cancer risk. In ACVR1, rs13395576[C] was associated with lower breast cancer risk overall (OR 0.84; 95% CI 0.72, 0.97) and for ER+ disease (OR 0.75; CI 0.62, 0.89) (p < 0.05). Rs1220110[A] and rs1220134[T] each had ORs of 0.89–0.90 for postmenopausal and ER+ breast cancer (p ≤ 0.03). Conversely, rs1682130[T] was associated with higher risk of ER+ breast cancer (OR 1.17; 95% CI 1.04, 1.32). Near AMH, rs6510652[T] had ORs of 0.85–0.90 for breast cancer overall and after menopause (p ≤ 0.02). Conclusions: The present results, from a large study of African American women, provide limited support for an association between AMH-related polymorphisms and breast cancer risk and require replication in other studies.

Original languageEnglish (US)
Pages (from-to)469-478
Number of pages10
JournalBreast Cancer Research and Treatment
Volume185
Issue number2
DOIs
StatePublished - Jan 2021

Bibliographical note

Funding Information:
This research was funded in part by the National Center for Advancing Translational Sciences (KL2-TR001109) and by the National Institutes of Health: P01 CA151135 (CBA, JRP, and AFO), UM1 CA164974 (JRP), R01 CA098663 (JRP), R01 CA100598 (CBA), P50 CA58223 (MAT, AO), U01 CA179715 (MAT); and by the Susan G. Komen Foundation (JRP), the Breast Cancer Research Foundation (CBA); and the University Cancer Research Fund of North Carolina. The results do not necessarily reflect the views of the NIH or the sponsors, who had no role in study design; data collection, analysis, or interpretation; or writing and submission of the manuscript. Acknowledgements

Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.

Keywords

  • Anti-Müllerian hormone
  • Breast cancer
  • Case–control
  • Genetic polymorphisms

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Genetic variants in anti-Müllerian hormone-related genes and breast cancer risk: results from the AMBER consortium'. Together they form a unique fingerprint.

Cite this